We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Biosimilars encircle Rituxan, US debates innovator exclusivity.
- Authors
Carey, Karen
- Abstract
The article reports on the phase 2 rheumatoid arthritis trial started by the Novartis generic drugs unit Sandoz with its own version of blockbuster monoclonal antibody (mAb) Rituxan in the U.S. in January 2011. It says that Sandoz joins Spectrum Pharmaceuticals of California and Teva Pharmaceuticals of Israel in working on versions of the anti-CD20 chimeric mAb approved for rheumatoid arthritis, non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The reasons why Rituxan has been prioritized by biosimilar manufacturers are also discussed.
- Subjects
RHEUMATOID arthritis; CLINICAL trials; SANDOZ Pharmaceuticals GmbH; NOVARTIS AG; SPECTRUM Pharmaceuticals Inc.; TEVA Pharmaceutical Industries Ltd.; BIOTECHNOLOGY
- Publication
Nature Biotechnology, 2011, Vol 29, Issue 3, p177
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0311-177